SG10201707449TA - Genetically modified non-human animals and methods of use thereof - Google Patents

Genetically modified non-human animals and methods of use thereof

Info

Publication number
SG10201707449TA
SG10201707449TA SG10201707449TA SG10201707449TA SG10201707449TA SG 10201707449T A SG10201707449T A SG 10201707449TA SG 10201707449T A SG10201707449T A SG 10201707449TA SG 10201707449T A SG10201707449T A SG 10201707449TA SG 10201707449T A SG10201707449T A SG 10201707449TA
Authority
SG
Singapore
Prior art keywords
methods
genetically modified
human animals
modified non
animals
Prior art date
Application number
SG10201707449TA
Inventor
Richard Flavell
Till Strowig
Markus G Manz
Chiara Borsotti
Madhav Dhodapkar
Andrew J Murphy
Sean Stevens
George D Yancopoulos
Original Assignee
Regeneron Pharma
Univ Yale
Inst For Res In Biomedicine (Irb)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Univ Yale, Inst For Res In Biomedicine (Irb) filed Critical Regeneron Pharma
Publication of SG10201707449TA publication Critical patent/SG10201707449TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/8572—Animal models for proliferative diseases, e.g. comprising an oncogene

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG10201707449TA 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of use thereof SG10201707449TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261722437P 2012-11-05 2012-11-05

Publications (1)

Publication Number Publication Date
SG10201707449TA true SG10201707449TA (en) 2017-10-30

Family

ID=49876957

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201707449TA SG10201707449TA (en) 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of use thereof
SG11201502685XA SG11201502685XA (en) 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201502685XA SG11201502685XA (en) 2012-11-05 2013-11-05 Genetically modified non-human animals and methods of use thereof

Country Status (20)

Country Link
US (5) US9901082B2 (en)
EP (4) EP3556206B1 (en)
JP (4) JP6422441B2 (en)
KR (5) KR102275412B1 (en)
CN (3) CN108401987B (en)
AU (3) AU2013337242B2 (en)
CA (1) CA2887706C (en)
DK (4) DK3556206T3 (en)
ES (3) ES2884598T3 (en)
FI (1) FI3939423T3 (en)
HK (2) HK1210380A1 (en)
IL (5) IL299887B1 (en)
MX (3) MX370856B (en)
MY (1) MY175400A (en)
NO (1) NO2946162T3 (en)
NZ (3) NZ724353A (en)
PT (4) PT3308641T (en)
RU (1) RU2673156C2 (en)
SG (2) SG10201707449TA (en)
WO (1) WO2014071397A2 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PT3417701T (en) 2009-10-06 2022-03-16 Univ Yale Genetically modified mice and engraftment
MX338971B (en) 2011-02-15 2016-05-06 Inst Res Biomedicine Irb Humanized m-csf mice.
US9820476B2 (en) * 2012-09-07 2017-11-21 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
NZ724353A (en) 2012-11-05 2022-05-27 Regeneron Pharma Genetically modified non-human animals and methods of use thereof
JP6444321B2 (en) 2013-02-22 2018-12-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Mice expressing humanized major histocompatibility gene complex
EP4269430A3 (en) 2013-09-23 2024-01-10 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized signal-regulatory protein gene
HUE033272T2 (en) 2013-10-15 2017-11-28 Regeneron Pharma Humanized il-15 animals
RU2700484C2 (en) 2014-04-08 2019-09-17 Регенерон Фармасьютикалз, Инк. NON-HUMAN ANIMALS HAVING HUMANIZED Fc-γ-RECEPTORS
SG10202003996YA (en) 2014-05-05 2020-06-29 Regeneron Pharma Humanized c5 and c3 animals
NO2785538T3 (en) 2014-05-07 2018-08-04
CN106536546B (en) * 2014-05-19 2021-04-30 再生元制药公司 Genetically modified non-human animals expressing human EPO
MX2016016903A (en) 2014-06-19 2017-03-27 Regeneron Pharma Non-human animals having a humanized programmed cell death 1 gene.
IL286414B2 (en) 2014-11-24 2024-04-01 Regeneron Pharma Non-human animals expressing humanized cd3 complex
IL286403B2 (en) 2014-12-05 2023-10-01 Regeneron Pharma Non-human animals having a humanized cluster of differentiation 47 gene
WO2016137841A1 (en) * 2015-02-26 2016-09-01 William Paterson University Of New Jersey Transgenic mice
MX2017012829A (en) 2015-04-06 2018-02-23 Regeneron Pharma Humanized t cell mediated immune responses in non-human animals.
WO2016168212A1 (en) * 2015-04-13 2016-10-20 Regeneron Pharmaceuticals, Inc. Humanized sirpa-il15 knockin mice and methods of use thereof
RU2745403C2 (en) 2015-11-20 2021-03-24 Регенерон Фармасьютикалз, Инк. Non-human animals having humanized lymphocyte-activation gene 3
DK3422845T3 (en) 2016-02-29 2021-08-30 Regeneron Pharma GNAGER WITH A HUMANIZED TMPRSS GENE
KR20190038613A (en) * 2016-08-11 2019-04-08 더 잭슨 래보라토리 Methods and compositions for improved human red blood cell survival in genetically modified immunodeficient non-human animals
JOP20190009A1 (en) 2016-09-21 2019-01-27 Alx Oncology Inc Antibodies against signal-regulatory protein alpha and methods of use
CN110740641A (en) * 2016-11-30 2020-01-31 杰克逊实验室 Humanized mouse model with improved human innate immune cell development
US11064685B2 (en) * 2017-02-27 2021-07-20 Regeneron Pharmaceuticals, Inc. Non-human animal models of retinoschisis
CN107115424B (en) * 2017-05-09 2018-05-29 江西樟树市正康医药生物科技有限公司 Change acidic constitution and protect calcium and clearing heat and detoxicating Chinese medicine composition and preparation method
CN115851834A (en) 2017-05-12 2023-03-28 杰克逊实验室 NSG mice deficient in class I and class II MHC
US11712026B2 (en) 2017-10-18 2023-08-01 The Jackson Laboratory Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
IL274740B2 (en) 2017-11-30 2024-06-01 Regeneron Pharma Non-human animals comprising a humanized trkb locus
AU2019240111A1 (en) 2018-03-21 2020-09-17 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
MA52177A (en) 2018-03-26 2021-02-17 Regeneron Pharma HUMANIZED RODENTS TO TEST THERAPEUTIC AGENTS
JP2021530970A (en) 2018-07-16 2021-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. DITRA non-human animal model and its use
CN111057721B (en) * 2018-10-12 2021-03-16 百奥赛图(北京)医药科技股份有限公司 Preparation method and application of humanized IL-4 and/or IL-4R alpha modified animal model
CN111172190B (en) * 2018-12-25 2021-07-30 百奥赛图江苏基因生物技术有限公司 Construction method and application of humanized cell factor CSF2 gene modified non-human animal
ES2966625T3 (en) 2019-04-04 2024-04-23 Regeneron Pharma Rodents comprising a humanized coagulation factor 12 locus
AU2020286382A1 (en) 2019-06-04 2021-11-04 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TTR locus with a beta-slip mutation and methods of use
EP3796776A1 (en) 2019-06-07 2021-03-31 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized albumin locus
CN111304246B (en) * 2019-12-17 2021-05-04 百奥赛图江苏基因生物技术有限公司 Humanized cytokine animal model, preparation method and application
KR20220125797A (en) * 2020-01-10 2022-09-14 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 Genetically Modified Non-Human Animals with Human or Chimeric MHC Protein Complexes
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
WO2024020057A1 (en) 2022-07-19 2024-01-25 Regeneron Pharmaceuticals, Inc. Genetically modified animal model and its use to model the human immune system

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5573930A (en) 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
JP2644794B2 (en) 1986-10-24 1997-08-25 カイロン コーポレイション A new type of colony stimulating factor-1
DE3853201T2 (en) 1987-12-23 1995-09-14 Univ Leland Stanford Junior Chimeric immunocompromising mammals and their use.
JP2981486B2 (en) 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート Mammalian immune system research methods
JP2935511B2 (en) * 1989-10-20 1999-08-16 忠三 岸本 Method for producing human IL-6 receptor
DE69131331T2 (en) 1990-01-15 2000-03-02 Yeda Res & Dev Permanent transplantation and development of human hematopoietic cell lines in normal mammals
US5652373A (en) 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US5849288A (en) 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
WO1991016910A1 (en) 1990-05-03 1991-11-14 Systemix, Inc. Human lymphoid tissue in an immunocompromised host
US5633426A (en) 1990-05-25 1997-05-27 Systemix, Inc. In vivo use of human bone marrow for investigation and production
CA2064075A1 (en) 1990-05-25 1991-11-26 Charles M. Baum Human peripheral blood cells in an immunocompromised host
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
EP0571525A1 (en) 1991-02-11 1993-12-01 OMMAYA, Ayub K. Spinal fluid driven artificial organ
EP0517199A1 (en) 1991-06-04 1992-12-09 Yeda Research And Development Company, Ltd. Durable engraftment of human tissue and cells in normal mammals
WO1993005796A1 (en) 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
EP0539970B1 (en) 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
US6353150B1 (en) 1991-11-22 2002-03-05 Hsc Research And Development Limited Partnership Chimeric mammals with human hematopoietic cells
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5866757A (en) 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US6018096A (en) 1993-05-03 2000-01-25 Surrogen, Inc. Animal model for engraftment, proliferation and differentiation of human hematopoietic stem cells
CA2103693A1 (en) 1993-08-06 1995-02-07 Steven Gallinger Animal model of the human immune system
CA2195678A1 (en) 1994-07-27 1996-02-08 Joseph A. Borkowski Bradykinin b2 receptor modified transgenic non-human animals
US6455756B1 (en) 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
US7273753B2 (en) 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
US6248721B1 (en) 1997-04-09 2001-06-19 Lung-Ji Chang Method of using mouse model for evaluation of HIV vaccines
JP4312265B2 (en) 1997-04-09 2009-08-12 ラング−ジ チャン Animal model for vaccine evaluation
GB2337755B (en) * 1998-05-29 2003-10-29 Secr Defence Virus vaccine
US20030028911A1 (en) 1999-08-31 2003-02-06 Manley Huang Transgenic mammal capable of facilitating production of donor-specific functional immunity
CA2382383A1 (en) 1999-08-31 2001-03-08 Genencor International, Inc. Transgenic mammal capable of facilitating production of donor-specific functional immunity
WO2001042484A1 (en) * 1999-12-09 2001-06-14 Human Genome Sciences, Inc. Il-6 like polynucleotide
AU2001290855A1 (en) 2000-09-14 2002-03-26 Genetrol Biotherapeutics, Inc. Method and cell composition for screening compounds for anti-inflammatory activity
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1414996T3 (en) * 2001-07-10 2011-03-21 Johnson & Johnson Res Pty Ltd Methods for Genetically Modifying Hematopoietic Progenitor Cells and Uses of Modified Cells
WO2003039232A2 (en) * 2001-10-26 2003-05-15 Large Scale Biology Corporation Endothelial cell derived hemotopoietic growth factor
EP1994824A1 (en) 2001-11-15 2008-11-26 Kirin Pharma Kabushiki Kaisha Chimeric non-human animal
AU2003281309A1 (en) 2002-07-05 2004-01-23 Kirin Beer Kabushiki Kaisha Novel undifferentiated stem cells contained in cord blood, bone marrow, peripheral blood or the like
CN101250553A (en) 2002-07-13 2008-08-27 上海医学遗传研究所 Human thrombopoietin expression vector and constructing method therefor
EP1539946A4 (en) 2002-09-09 2006-03-15 California Inst Of Techn Methods and compositions for the generation of humanized mice
EP1418185A1 (en) 2002-11-11 2004-05-12 Aventis Pharma Deutschland GmbH Use of EDG2 receptor in an animal model of heart failure
CA2507882A1 (en) 2002-12-16 2004-07-22 Genentech, Inc. Transgenic mice expressing human cd20
MXPA05009743A (en) * 2003-03-12 2006-03-09 Genentech Inc Use of bv8 and/or eg-vegf to promote hematopoiesis.
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
US7294754B2 (en) 2004-10-19 2007-11-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
US7759541B2 (en) 2004-12-13 2010-07-20 Iti Life Sciences Transgenic animals for assessing drug metabolism and toxicity
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
PT2019683T (en) 2006-04-25 2017-03-17 Univ California Administration of growth factors for the treatment of cns disorders
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
WO2008060360A2 (en) 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
WO2008069659A1 (en) 2006-12-05 2008-06-12 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Improved xenogenic immune system in a non-human mammal
JP5666903B2 (en) 2007-05-23 2015-02-12 サンガモ バイオサイエンシーズ， インコーポレイテッド Methods and compositions for enhancing transgene expression
GB0718029D0 (en) 2007-09-14 2007-10-24 Iti Scotland Ltd Two step cluster deletion and humanisation
US20110118446A1 (en) 2007-09-28 2011-05-19 The General Hospital Corporation Methods and compositions for antibody production
WO2009097468A2 (en) 2008-01-29 2009-08-06 Kliman Gilbert H Drug delivery devices, kits and methods therefor
EP2419113B1 (en) * 2009-04-13 2017-05-10 Apceth GmbH & Co. KG Engineered mesenchymal stem cells and method of using same to treat tumors
US20120251528A1 (en) 2009-06-29 2012-10-04 Leskov Ilya B Non-Human Mammal Model Of Human Hematopoietic Cancer
JP2012531896A (en) 2009-06-29 2012-12-13 チェン，チンフェン Method for producing a humanized non-human mammal
RU2425880C2 (en) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Method of producing transgene mice
PT3417701T (en) 2009-10-06 2022-03-16 Univ Yale Genetically modified mice and engraftment
CA3000246C (en) * 2009-12-21 2021-05-25 Regeneron Pharmaceuticals, Inc. Humanized fc.gamma.r mice
EP2618656B1 (en) * 2010-09-20 2018-06-20 Yale University, Inc. HUMAN SIRPalpha TRANSGENIC ANIMALS AND THEIR METHODS OF USE
WO2012051572A1 (en) 2010-10-15 2012-04-19 Massachusetts Institute Of Technology A humanized non-human mammal model of malaria and uses thereof
MX338971B (en) 2011-02-15 2016-05-06 Inst Res Biomedicine Irb Humanized m-csf mice.
RU2751240C2 (en) 2011-10-28 2021-07-12 Регенерон Фармасьютикалс, Инк. Humanized il-6 and il-6 receptor
US9820476B2 (en) 2012-09-07 2017-11-21 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
NZ724353A (en) 2012-11-05 2022-05-27 Regeneron Pharma Genetically modified non-human animals and methods of use thereof
EP4269430A3 (en) 2013-09-23 2024-01-10 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized signal-regulatory protein gene
HUE033272T2 (en) 2013-10-15 2017-11-28 Regeneron Pharma Humanized il-15 animals
CN106536546B (en) 2014-05-19 2021-04-30 再生元制药公司 Genetically modified non-human animals expressing human EPO
WO2016168212A1 (en) 2015-04-13 2016-10-20 Regeneron Pharmaceuticals, Inc. Humanized sirpa-il15 knockin mice and methods of use thereof

Also Published As

Publication number Publication date
EP3939423A1 (en) 2022-01-19
IL311744A (en) 2024-05-01
US20240099278A1 (en) 2024-03-28
CA2887706C (en) 2022-08-02
AU2013337242B2 (en) 2019-04-04
ES2884598T3 (en) 2021-12-10
KR20210087567A (en) 2021-07-12
WO2014071397A2 (en) 2014-05-08
EP3556206B1 (en) 2021-06-02
CA2887706A1 (en) 2014-05-08
RU2018140189A3 (en) 2022-05-04
DK3308641T3 (en) 2019-10-07
MY175400A (en) 2020-06-24
EP3939423B1 (en) 2024-03-06
PT3939423T (en) 2024-05-29
US11778995B2 (en) 2023-10-10
WO2014071397A3 (en) 2014-06-26
IL299887B1 (en) 2024-05-01
KR102649893B1 (en) 2024-03-25
US20210100228A1 (en) 2021-04-08
KR102275412B1 (en) 2021-07-12
NZ724353A (en) 2022-05-27
KR20240042142A (en) 2024-04-01
EP3308641B1 (en) 2019-07-03
MX2019015882A (en) 2020-02-07
CN104918483B (en) 2018-05-11
JP7105844B2 (en) 2022-07-25
DK3556206T3 (en) 2021-08-09
HK1210380A1 (en) 2016-04-22
RU2673156C2 (en) 2018-11-22
EP3308641A1 (en) 2018-04-18
EP2914102B1 (en) 2017-10-18
EP3556206A1 (en) 2019-10-23
NO2946162T3 (en) 2018-06-09
PT2914102T (en) 2018-01-15
JP2022132376A (en) 2022-09-08
US9901082B2 (en) 2018-02-27
CN104918483A (en) 2015-09-16
CN114766432A (en) 2022-07-22
RU2015121195A (en) 2016-12-27
PT3308641T (en) 2019-10-24
JP6422441B2 (en) 2018-11-14
AU2019204775A1 (en) 2019-07-25
SG11201502685XA (en) 2015-05-28
JP2015534819A (en) 2015-12-07
IL270124B2 (en) 2023-06-01
IL258968B (en) 2019-10-31
CN108401987B (en) 2022-04-29
IL238478B (en) 2018-05-31
DK2914102T3 (en) 2017-12-11
MX2020012427A (en) 2022-06-08
MX2015005654A (en) 2016-04-28
IL258968A (en) 2018-06-28
FI3939423T3 (en) 2024-05-23
NZ749626A (en) 2023-11-24
PT3556206T (en) 2021-08-24
ES2655442T3 (en) 2018-02-20
DK3939423T3 (en) 2024-05-06
HK1253909A1 (en) 2019-07-05
RU2018140189A (en) 2018-12-10
AU2013337242A1 (en) 2015-04-30
KR20150081285A (en) 2015-07-13
IL299887A (en) 2023-03-01
US20160366862A1 (en) 2016-12-22
IL270124A (en) 2019-12-31
ES2748662T3 (en) 2020-03-17
KR20220075242A (en) 2022-06-07
KR20220148307A (en) 2022-11-04
IL238478A0 (en) 2015-06-30
US20180049413A1 (en) 2018-02-22
US9986724B2 (en) 2018-06-05
JP2021010371A (en) 2021-02-04
US20140134662A1 (en) 2014-05-15
EP2914102A2 (en) 2015-09-09
KR102458016B1 (en) 2022-10-25
CN108401987A (en) 2018-08-17
MX370856B (en) 2020-01-08
JP2019037238A (en) 2019-03-14
US10785968B2 (en) 2020-09-29
AU2022200302A1 (en) 2022-02-10
KR102402806B1 (en) 2022-05-30
AU2019204775B2 (en) 2021-10-21
JP6772234B2 (en) 2020-10-21
IL270124B1 (en) 2023-02-01
NZ631614A (en) 2016-10-28

Similar Documents

Publication Publication Date Title
IL282472A (en) Genetically modified non-human animals and methods of use thereof
IL258968A (en) Genetically modified non-human animals and methods of use thereof
EP2827707A4 (en) Non-human animal models of depression and methods of use thereof
EP2863736A4 (en) Genetically modified animals and methods for making the same
IL224327B (en) Transgenic animals and methods of use
EP2678434A4 (en) Genetically modified animals and methods for making the same
GB201216564D0 (en) Genetically edited animal
GB201505771D0 (en) Protective case and methods of making
EP2912178A4 (en) Super-enhancers and methods of use thereof
EP2770823A4 (en) Transgenic animals and methods of use
EP2618656A4 (en) HUMAM SIRPAalpha TRANSGENIC ANIMALS AND THEIR METHODS OF USE
PL2852279T3 (en) Animal brushing arrangement and method of operating animal brushing arrangement
EP2852397A4 (en) Huwentoxin-iv variants and methods of use
IL245306A0 (en) Compositions and methods for producing genetically modified animals
IL290429A (en) Improved methods of genetically modifying animal cells
HK1211177A1 (en) Cloned non-human animals free of selective markers
EP2836068A4 (en) Hoof trimming chute and application
GB201216939D0 (en) Gebetically modified non-human mammal and uses thereof